![Iris Löw-Friedrich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Iris Löw-Friedrich
Director Ejecutivo en ZOGENIX, INC. .
Fortuna: 126 846 $ al 30/06/2025
Perfil
La Dra. Iris Lw-Friedrich es vicepresidenta del Consejo de Supervisión de Evotec SE, directora médica y vicepresidenta ejecutiva de UCB SA y profesora de la Johann Wolfgang Goethe-Universitt Frankfurt am Main. Forma parte del Consejo de Administración de Fresenius SE & Co. KGaA y Evotec SE. Anteriormente, la Dra. Lw-Friedrich fue presidenta de Transcelerate Biopharma, Inc., miembro del Consejo de Supervisión de Heidelberg Pharma AG, directora de Investigación y Desarrollo de UCB Pharma GmbH, vicepresidenta de Proyectos Globales de BASF Pharma, vicepresidenta de Desarrollo Clínico de Hoechst AG, directora de Gestión Clínica Global y vicepresidenta de Aventis Pharma AG y vicepresidenta de Desarrollo Clínico de Hoechst Marion Roussel, Inc. Se doctoró en la Johann Wolfgang Goethe-Universitt Frankfurt am Main.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
EVOTEC SE 0,01 % | 31/12/2024 | 15.000 ( 0,01 % ) | 126 846 $ | 30/06/2025 |
| 18/06/2025 | 0 ( -.--% ) | - $ | 30/06/2025 |
Últimas noticias acerca de Iris Löw-Friedrich
Cargos activos de Iris Löw-Friedrich
| Empresas | Cargo | Inicio |
|---|---|---|
| EVOTEC SE | Presidente | 15/06/2021 |
| FRESENIUS SE & CO. KGAA | Director/Miembro de la Junta | 13/05/2016 |
| ZOGENIX, INC. | Director Ejecutivo | - |
| SWEDISH ORPHAN BIOVITRUM AB | Director/Miembro de la Junta | 08/05/2025 |
| SATELLOS BIOSCIENCE INC. | Director/Miembro de la Junta | 18/06/2025 |
PhRMA Foundation
 PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services PhRMA Foundation engages in research and development of drugs. The non-profit company is based in Washington, DC. | Director/Miembro de la Junta | 01/04/2019 |
Johann Wolfgang Goethe-Universität Frankfurt am Main | Corporate Officer/Principal | 01/01/2000 |
Antiguos cargos conocidos de Iris Löw-Friedrich.
| Empresas | Cargo | Fin |
|---|---|---|
| UCB | Director Técnico/Científico/I+D | 01/01/2024 |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Presidente | 01/09/2017 |
| ░░░ ░░░░░░ ░░░░ | ░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formación de Iris Löw-Friedrich.
Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 7 |
|---|---|
| UCB | Health Technology |
| HEIDELBERG PHARMA AG | Health Technology |
| EVOTEC SE | Health Technology |
| BASF SE | Producer Manufacturing |
| FRESENIUS SE & CO. KGAA | Health Services |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| SATELLOS BIOSCIENCE INC. | Health Technology |
| Empresas privadas | 8 |
|---|---|
Hoechst Marion Roussel, Inc. | Health Technology |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Health Technology |
UCB Pharma GmbH
 UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. | Health Technology |
Hoechst AG
 Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
Aventis Pharma AG | |
BASF Pharma | |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services PhRMA Foundation engages in research and development of drugs. The non-profit company is based in Washington, DC. | Commercial Services |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Iris Löw-Friedrich
